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Megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) is
a congenital visceral myopathy characterized by severe dilation of the
urinary bladder and defective intestinal motility. The genetic basis of
MMIHS has been ascribed to spontaneous and autosomal dominant
mutations in actin gamma 2 (ACTG2), a smooth muscle contractile
gene. However, evidence suggesting a recessive origin of the disease
also exists. Using combined homozygosity mapping and whole
exome sequencing, a genetically isolated family was found to carry
a premature termination codon in Leiomodin1 (LMOD1), a gene pref-
erentially expressed in vascular and visceral smooth muscle cells. Par-
ents heterozygous for the mutation exhibited no abnormalities, but
a child homozygous for the premature termination codon dis-
played symptoms consistent with MMIHS. We used CRISPR-Cas9
(CRISPR-associated protein) genome editing of Lmod1 to generate
a similar premature termination codon. Mice homozygous for the
mutation showed loss of LMOD1 protein and pathology consistent
with MMIHS, including late gestation expansion of the bladder,
hydronephrosis, and rapid demise after parturition. Loss of
LMOD1 resulted in a reduction of filamentous actin, elongated
cytoskeletal dense bodies, and impaired intestinal smooth muscle
contractility. These results define LMOD1 as a disease gene for
MMIHS and suggest its role in establishing normal smooth muscle
cytoskeletal–contractile coupling.
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Megacystis microcolon intestinal hypoperistalsis syndrome(MMIHS) (MIM155310) is a rare congenital defect of
visceral smooth muscle, primarily affecting females who present
at birth with functional obstruction of intestine, microcolon, di-
lation of bladder, and secondary hydronephrosis. More than
250 cases have been reported since the initial description of
MMIHS in five young girls in 1976 (1–3). Total parenteral nu-
trition (TPN), adequate intermittent catheterization of bladder,
and surgical corrections for intestinal malrotation are frequent
modes of treatment for this disease without which rapid death
ensues. In some instances, multivisceral organ transplantation
has been indicated with some success. Despite these clinical in-
terventions, MMIHS often leads to premature death due to
complications of therapy (3, 4).
The majority of MMIHS cases are sporadic, stemming from de
novo, heterozygous missense mutations in the smooth muscle-
restricted ACTG2 gene (5, 6). These mutations are thought to
render the ACTG2 protein defective for normal actin polymer-
ization and contractile activity in visceral smooth muscle organs
although formal in vivo proof for this ACTG2 loss of function is
lacking (6, 7). Heterozygous mutations in ACTG2 are also ob-
served in patients with autosomal dominant MMIHS (6, 8), but
there is emerging evidence for a recessive mode of inheritance.
For example, a homozygous loss-of-function variant in the my-
osin heavy chain 11 (MYH11) gene, which is another highly
specific contractile gene for smooth muscle lineages (9), was
reported in a patient with MMIHS from a consanguineous (i.e.,
genetically related) couple (10). To date, no other smooth
muscle-restricted contractile genes have been linked to MMIHS.
In this report, a patient with MMIHS is described from a
consanguineous couple in whom no variants of ACTG2 or
MYH11 were found. Rather, an autosomal recessive inherited
subtype of MMIHS has been discovered involving a homozygous
nonsense mutation in Leiomodin1 (LMOD1), an understudied
smooth muscle-restricted gene (11) that is a direct target of the
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serum response factor (SRF)/Myocardin transcriptional switch
(12). CRISPR-Cas9 (CRISPR-associated protein) genome edit-
ing of the murine Lmod1 gene resulted in a similar nonsense
mutation and a nearly identical MMIHS phenotype. Functional
studies in both human and mouse support a previously un-
recognized role for LMOD1 in visceral smooth muscle func-
tion. We conclude that LMOD1 is an MMIHS disease gene
that expands the genetic heterogeneity of this devastating
visceral myopathy.
Results
Clinical Case Study of a Neonate with MMIHS. The affected proband
was a female neonate from a consanguineous couple, originating
from a genetic isolate in the Netherlands. Most of the inhabitants
in this region are descendants of a small group of founders; a
plague epidemic in the 17th century killed the majority of the
population, except for 151 inhabitants that survived (13, 14).
During a routine ultrasound sonography (USG) examination at
20 wk gestation, a distended bladder (megacystis) and bilateral
hydronephrosis, a condition that typically occurs when the kidney
swells due to the failure of normal drainage of urine from the
kidney to the bladder, were detected (Fig. 1A); bladder disten-
tion and hydronephrosis are common features of MMIHS
that are not evident in normal age-matched controls (Fig. 1B).
Polyhydramnios, an excess of amniotic fluid in the amniotic sac,
was later acknowledged, and delivery was medically induced at 34 wk
gestation due to mechanical problems of the mother. Physical
examination in the neonatal period revealed distended and lax
abdominal wall, causing the intestine to be externally palpable.
Further postnatal USG investigation did not reveal abnormali-
ties of the heart or brain. Hydronephrosis, bilateral distention of
the proximal ureter, and distended bladder were persistent
during postnatal life of the patient. No peristaltic movement of
the gastrointestinal tract was noted. Evidence of a microcolon
was demonstrated through a barium enema test (Fig. 1A). Con-
ventional treatments included TPN, stomach suction, and cathe-
terization of the atonic bladder. Because the patient died at 5 d of
age due to sepsis, there were no further clinical measures. Although
the patient was the first child in the family diagnosed with MMIHS,
the parents acknowledged a previous intrauterine fetal death in
which routine 20 wk USG detected abdominal distention of the
fetus. Two other siblings in this family are healthy and show no signs
of bladder or intestinal abnormalities (Fig. 1C).
Copy Number Variation Profiling and Homozygosity Mapping. Seven
large copy number variants (CNVs) were identified, all of which
were common polymorphisms inherited from one of the un-
affected parents. Runs of homozygosity (ROH) larger than 1 Mb
within the neonate were considered to be inherited by descent
because these regions were heterozygous in the parental samples
and contained over 50 consecutive homozygous probes (SI Ap-
pendix, Table S1). These putative inherited-by-descent regions
contained 19 recessive single nucleotide polymorphisms (SNPs)
with a minor allele frequency below 1% (SI Appendix, Table S2).
Only three of these variants were predicted to be deleterious.
The degree of parental relatedness was determined by F statistics
using all ROH larger than 1 Mb and at least 50 consecutive
probes using the Genomic Oligoarray and SNP array evaluation
tool v3.0. An F value ≥ 0.0156 indicates a progeny from a con-
sanguineous marriage (15). Father (F = 0.015625 and 64 Mb of
ROH), mother (F = 0.03125 and 86 Mb of ROH), and patient
(F = 0.046875 and 115 Mb of ROH) had a relatively high F number
(13, 14), suggesting that the patient was indeed a progeny from a
consanguineous couple and that the parents originated from a ge-
netically isolated population (13).
A Homozygous Nonsense Mutation of LMOD1 in the MMIHS Patient.
Targeted analysis of the exome data identified no deleterious
variants in the known disease genes, ACTG2 and MYH11. In
total, 526 variants had a minor allele frequency below 0.1%.
Prioritization to yield the most likely deleterious variants resulted
in the identification of 70 variants in total: 7 were nonsense vari-
ants, 10 were predicted to affect splicing, and 53 had a Combined
Annotation Dependent Depletion (CADD) score of ≥20, which is
indicative of possible pathogenicity. Only 3 out of 70 variants were
homozygous. One was a missense variant in the Interleukin24 gene
(NM_001185156.1:c.541T>G; p.Leu181Val). This variant was rel-
atively frequent in the normal population (minor allele frequency
of 0.4%), making it an unlikely candidate for the MMIHS phe-
notype. The two remaining recessive variants were rare: One
resulted in an intronic SNP predicted to affect splicing of Cellular
Repressor of E1A Stimulated Genes 2 (CREG2) (NM_153836.3:
c.442-5G>A), and the other resulted in a premature termination
codon (PTC) in exon two of Leiomodin1 (LMOD1) (NM_012134.2:
c.1108C>T; p.Arg370*). These two recessive variants are each lo-
cated within a large ROH (SI Appendix, Table S2). CREG2 is
expressed primarily in brain (16) whereas the LMOD1 gene exhibits
mRNA and protein expression in both bladder and intestine, and
the encoded protein is part of the smooth muscle network of
cytocontractile elements (11, 12). Further, we showed that the PTC
in LMOD1 disrupted normal mRNA and protein expression in
dermal fibroblasts derived from the proband compared with control
fibroblasts (Fig. 1D). Sanger sequencing confirmed that both par-
ents carried one copy of the PTC whereas the proband was ho-
mozygous, suggesting a recessive mode of inheritance (Fig. 1C). Of
note, the parents exhibited no MMIHS-like symptoms. These
findings prompted us to consider LMOD1 as the most likely can-
didate gene underlying MMIHS in the proband.
Fig. 1. Loss-of-function mutation in LMOD1 gene of an MMIHS patient.
(A) Timed ultrasonography at 28, 30, and 32 wk of gestation showing dis-
tended bladder (Bl) and hydronephrotic kidney (K). A postnatal barium
enema confirmed MMIHS (Far Right); white arrow and arrowhead indicate
the sigmoid colon and descending colon, respectively. (B) In utero ultraso-
nography of control (a and c) and MMIHS patient (b and d) demonstrating
megacystis (Bl) and hydronephrosis (K) in the MMIHS patient. (C) Pedigree of
the consanguineal family and results of Sanger sequencing. A heterozygous
variant is identified in DNA of the parents and a homozygous variant generating
a PTC (TGA) is detected in the proband. (D) RT-qPCR analysis of LMOD1 using
RNA from control and patient-derived dermal fibroblasts. (Inset) Protein ex-
pression of LMOD1 in control (Ctrl) and patient dermal fibroblasts. Data shown
are the mean expression of LMOD1 ± SD of three controls and the patient,
performed in triplicate. ***P < 0.001 by unpaired t test.
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LMOD1 Expression in Human Intestinal and Bladder Smooth Muscle.
Evidence exists for LMOD1 protein expression in smooth muscle
of the developing mouse embryo (12). To extend these findings
to human, immunohistochemical studies were undertaken in the
developing intestine and bladder. Intense staining of LMOD1
protein was observed in both visceral and vascular smooth muscle
of the intestine and bladder over a number of developmental time
points (SI Appendix, Fig. S1). Further evidence for LMOD1 protein
in these tissues was demonstrated by Western blotting (SI Appendix,
Fig. S1). These findings, coupled with the sharp reduction in
LMOD1 mRNA and LMOD1 protein in dermal fibroblasts of the
proband compared with control cells (Fig. 1D), support LMOD1 as
a disease gene for MMIHS.
CRISPR-Cas9 Genome Editing of the Mouse Lmod1 Gene. To provide
more formal proof of an association between loss in LMOD1 and
MMIHS, we turned to CRISPR-Cas9 genome editing in the mouse.
Initial efforts to inactivate Lmod1 were based on transgenic studies
showing the critical importance of two conserved SRF-binding
CArG boxes for Lmod1 promoter activity in vivo (12) and a more
recent report that revealed near abolishment of target gene ex-
pression upon CRISPR-Cas9 genome editing of a single CArG box
(17). In contrast to the latter finding, there was little change in
Lmod1 mRNA or LMOD1 protein in mice homozygous for three-
component CRISPR genome editing (18) of both CArG boxes (SI
Appendix, Fig. S2). Moreover, homozygous Lmod1 CArG-null mice
were viable and fertile and showed no overt signs of pathology.
These results suggest that the two proximal CArG boxes are dis-
pensable for LMOD1 expression and normal smooth muscle cell
(SMC) function in mice.
Parallel studies using two-component CRISPR genome editing
(18) of the first exon of Lmod1 resulted in a 151-bp deletion (Fig. 2
A and B). Sequence analysis showed that the deletion preserved the
first eight amino acids of LMOD1 but introduced an 11-aa
frameshift followed by a PTC (Fig. 2C). Using CRISPResso (19),
we did not detect any off-targeted events for any of the guide RNAs
(SI Appendix, Table S3). Intercrossing heterozygous mice revealed
an expected Mendelian ratio of live born pups (Fig. 2D). Western
blotting showed a twofold decrease in LMOD1 protein in stomach
of heterozygous mice whereas undetectable levels were observed in
homozygous mice (hereafter referred to as Lmod1−/−) (Fig. 2E).
Similar findings were noted in aorta and bladder (SI Appendix, Fig.
S3 A and B). Compound heterozygous mice in which one Lmod1
allele had both CArG boxes mutated and the other allele carried
the 151-bp deletion exhibited even lower levels of LMOD1 protein;
however, such compound heterozygous mice were without notice-
able defect, indicating a low-level threshold of LMOD1 protein
exists for normal homeostasis (SI Appendix, Fig. S3B). Loss of
LMOD1 expression had little to no effect on the expression of
other SMC contractile proteins (SI Appendix, Fig. S3B). Taken
together, these CRISPR-Cas9 genome editing results highlight
salient differences in phenotypic outcome dependent upon the
strategy employed.
Lmod1−/− Mice Exhibit an MMIHS-Like Phenotype. Consistent with
the above homozygous LMOD1 neonatal child, Lmod1−/− mice
displayed distention of the bladder beginning at 18.5 d of em-
bryonic development (Fig. 3A). In some cases, the developing
bladder expanded to such a great extent as to encroach upon the
abdominal cavity (Fig. 3B). Further histological analysis revealed
early onset thinning of detrusor muscle of the bladder in
Lmod1−/− mice whereas fewer histological changes were seen in
intestine and stomach (Fig. 3C). Expression of LMOD1 protein
coincided with ACTA2 in bladder, intestine, and stomach of WT
mice whereas mutant mice showed the expected loss in
LMOD1 protein (Fig. 3C). After parturition and the first feed-
ing, 100% of homozygous mutant mice showed enlargement of
the stomach and urinary bladder (Fig. 4 A and B), the latter of
which is consistent with clinical observations in human MMIHS
patients. Hydronephrosis, due to the failure of urine emptying
into the bladder, was noted in some mutant mice (Fig. 4 C and D).
Histological analysis of postnatal mice demonstrated thinning
and compaction of the visceral smooth muscle layers in both
stomach and bladder, along with severe loss of the transitional
epithelium of the bladder (Fig. 4E and SI Appendix, Fig. S4).
Immunofluorescence microscopy of Lmod1−/− tissues of post-
natal mice showed the absence of LMOD1 protein within
smooth muscle layers of the stomach, bladder, and intestine; the
Fig. 2. Two-component CRISPR genome editing of mouse Lmod1.
(A) Schematic of targeting strategy to disrupt exon one of Lmod1. Injection
of Cas9 mRNA and three guide RNAs (red arrowheads) resulted in deletion
of 151 bp (red) within exon one of the mouse Lmod1 gene. PCR primers
(blue triangles) were used to confirm deletion and sequence changes.
(B) PCR products generated with forward and reverse primers (shown in A)
indicating WT (+/+), heterozygous (+/−), and homozygous (−/−) deletion of
Lmod1. (C) Deletion of the 151-bp region resulted in a frameshift of the ORF
and the introduction of a PTC within Lmod1. WT amino acid is in black, and
the frame-shifted sequence is in red (asterisk denotes the UGA stop codon).
(D) Number of live-born pups of each genotype from heterozygous in-
tercross (P = 0.79 versus expected Mendelian numbers by χ2 test).
(E) Western blotting of LMOD1 protein in stomach of different Lmod1
genotypes.
Fig. 3. MMIHS phenotype in Lmod1−/− mice at embryonic (e) day 18.5.
(A) Gross pathology showing distended bladder in Lmod1−/− mice at e18.5
(white arrow and white bracket) compared with Lmod1+/+ littermate con-
trol. (B) H&E staining shows distended bladder and stomach in the same
plane of section from an e18.5 Lmod1−/− mouse. (Scale bar: 1 mm.) (C) H&E
staining and immunofluorescence staining of indicated SMC marker proteins
in sections of bladder, intestine, and stomach from e18.5 Lmod1−/− versus
Lmod1+/+ mice. (Scale bars: 100 μm.)
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apparent positive staining in some mutant tissues here and below
is attributable to occasional nonspecific staining of the primary
antibody (Fig. 4E and SI Appendix, Fig. S4). All segments of the
small intestine exhibited loss of LMOD1 protein expression, with
little evidence of overt histopathology (Fig. 5). There was a
significant increase in Ki67 staining of SMCs in the outer lon-
gitudinal layer of the intestine (SI Appendix, Fig. S5 A and B),
but no obvious signs of cell death as measured by TUNEL
staining (SI Appendix, Fig. S5C). Interestingly, a significant decrease
in intestinal length was noted in Lmod1−/− mice (SI Appendix, Fig.
S6 A and B), but there was no evidence of a microcolon (SI Ap-
pendix, Fig. S6C). Further, there were no obvious signs of histopa-
thology in Lmod1−/− aorta or esophagus, despite the absence of
LMOD1 protein within SMCs of these tissues (SI Appendix, Fig.
S6D). Comparative analysis of human and mouse LMOD1 protein
revealed 82% primary amino acid homology, similar domain
structure, and the relative positions of each PTC (SI Appendix,
Fig. S7). Taken together, these findings demonstrate an analogous
MMIHS-like phenotype in both human and mice lacking LMOD1.
Cytoskeletal–Contractile Defects with Deficiency of LMOD1. To begin
gaining mechanistic insight into how loss of LMOD1 leads to the
characteristic hypoperistalsis in MMIHS, we performed biochemical
and functional studies in cultured human intestinal smooth muscle
cells (hiSMCs). siRNA knockdown of LMOD1 in purified hiSMCs
resulted in a reduction of filamentous actin pelleted by ultracentri-
fugation (Fig. 6A). To determine whether there was a functional loss
of contractile competence in LMOD1-deficient hiSMCs, a collagen
gel contraction assay was used. Results showed a 40% decrease
in contractile activity in hiSMCs with reduced LMOD1 (Fig. 6B).
We next turned to the Lmod1−/− mouse model of MMIHS.
Ultracentrifugation and phalloidin staining showed a reduction
in filamentous actin in the Lmod1−/− mouse (SI Appendix, Figs.
S8 and S9). Surprisingly, however, there was little evidence of
ultrastructural actin filament perturbations in the bladder or
intestine of Lmod1−/− mice. However, a notable defect was ob-
served in dense bodies of bladder detrusor SMCs (Fig. 7 A–D
and SI Appendix, Fig. S10) and, to a lesser extent, intestine (SI
Appendix, Fig. S10). The changes in dense bodies were quite
pervasive in two independent mutant animals, and these struc-
tures bore some resemblance to nemaline bodies that were re-
cently described in humans carrying mutations in LMOD3 (20)
although the structures reported here lacked the characteristic
145-Å periodicity of cross-striations (Fig. 7D). The length of
dense bodies in longitudinally oriented SMCs of Lmod1−/− mice
was nearly three times greater than WT controls (Fig. 7E).
Further, there was a twofold decrease in the concentration of
dense bodies in mutant bladder (Fig. 7F). Collectively, these
results suggest ultrastructural changes in the normal cytoskeleton
of visceral SMCs in Lmod1−/− mice.
To assess the functional consequence of loss in LMOD1 in the
intestinal tract, we performed physiological measures of passive
tensile strength and contractile competence. Myography experi-
ments revealed a notable lack of tensile strength in jejunum ring
segments of Lmod1−/− mice as indicated by a lower level of
passive tension in response to mechanical expansion (Fig. 8A and
Fig. 4. MMIHS phenotype in postnatal Lmod1−/− mice. (A) Gross image of
Lmod1+/+ (leftmost) and Lmod1−/− (rightmost) pups showing abdominal
distention in the mutant due to bladder and milk-filled stomach (Top). A
higher magnified image of a mutant is shown at Bottom. (B) Dissected gross
images of stomach and bladder from indicated Lmod1 genotypes. (C) Dis-
sected kidneys and hydronephrosis in some postnatal day 5 Lmod1−/− mice.
(D) H&E-stained sections of kidneys from each genotype. Note the large
renal cysts in the Lmod1−/− section, representing evidence of previously
retained water in the mutant kidneys. (E) Sections of Lmod1+/+ versus
Lmod1−/− stomach and bladder stained with H&E (Top row) or antibodies to
the indicated proteins. DAPI nuclear stain was pseudocolored white. (Scale
bars: H&E sections, 100 μm; immunofluorescence sections, 50 μm.)
Fig. 5. Histology and LMOD1 immunofluorescence in three segments of
intestine. H&E-stained sections of duodenum, jejunum, and ileum (Left col-
umn) and immunofluorescence microscopy of ACTA2 and LMOD1 show
absence of LMOD1 protein in visceral smooth muscle of intestinal segments
of Lmod1−/−mice. [Scale bars: H&E sections, 100 μm (vertical line at Top Left);
immunofluorescence sections, 50 μm (Bottom Right).] Note, the apparent faint
immunostaining for LMOD1 in mutants is nonspecific (SI Appendix, Fig. S4).
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SI Appendix, Fig. S11A). Importantly, a more than threefold
decrease in KCL- or carbachol-induced contractility was dem-
onstrated in intestinal ring segments from Lmod1−/− mice (Fig. 8
B and C). These results suggest that loss in LMOD1 protein
expression leads to compromised structural integrity and impaired
contraction of visceral smooth muscle-containing tissues. The
near identical phenotypes found in human and mouse support
the notion that loss in LMOD1 leads to the functional ob-
struction of intestine and urinary bladder commonly seen in
MMIHS.
Discussion
Previous studies have documented spontaneous and autosomal
dominant mutations in ACTG2 or a recessive mutation in
MYH11 in patients diagnosed with MMIHS, a rare congenital
disease in visceral smooth muscle of the intestine and urinary
bladder (8, 10). However, there is emerging evidence for con-
siderable heterogeneity in the disease, and additional recessive
mutations are likely (4). In this report, we have identified an SNP
resulting in a premature termination codon (PTC) within exon
two of human LMOD1 in a family from a genetically isolated
population (13). Although the heterozygous parents exhibited no
discernable disease, the homozygous neonate displayed classic
signs of MMIHS, both in utero and after parturition. The PTC
severely reduced expression of LMOD1 in patient-derived der-
mal fibroblasts. The fact that mice homozygous for a similar PTC
located in exon one of Lmod1 exhibited loss of LMOD1 protein
and phenotypes analogous to those seen in the homozygous
neonatal child strongly supports LMOD1 as a disease gene for
MMIHS. Indeed, both the affected child and homozygous mu-
tant mice displayed the highly penetrant megacystis (distended
bladder) during prenatal and postnatal development. The dis-
tended bladder likely precipitated hydronephrosis, a trait also
observed in patients diagnosed with MMIHS.
Another pathognomonic feature of human MMIHS is in-
testinal hypoperistalsis (2). In mice homozygous for the PTC in
Lmod1, as well as cultured human intestinal SMCs deficient in
LMOD1, a dramatic decrease in agonist-induced contractility
was observed. Intestinal hypoperistalsis likely caused the gas-
troparesis observed in all mutant mice; it is noteworthy that
failure to empty the stomach has also been reported in some
cases of human MMIHS (4). We were unable to observe in-
testinal transit due to technical limitations inherent in gavage-
feeding neonatal mice. One notable difference between the child
and mice null for Lmod1 was the absence of a microcolon in
mutant mice. It is unclear as to why this aspect of the disease was
not manifest in the Lmod1-null mouse. Nevertheless, the weight
of evidence supports an expansion of the heterogeneity of
MMIHS by showing a direct link between nonsense mutations in
LMOD1 and clinical and experimental cases of the disease.
LMOD1 was originally cloned from a human thyroid cDNA
library (21) and subsequently was shown to be enriched in
smooth muscle-containing tissues (22). An early report showed
that the amino terminus of LMOD1 binds tropomyosins in an
isoform-specific manner (23). We now recognize LMOD1 as one
of three gene paralogs that function in the nucleation of actin
monomers in association with tropomyosin (20, 24, 25). Recent
gene knockout experiments have further illuminated the role of
LMOD family members. For example, Lmod2 knockout mice
exhibit shortened cardiac actin filaments and dilated cardiomy-
opathy although no known LMOD2 mutations have been un-
covered in humans (26). On the other hand, human mutations in
LMOD3 are linked to nemaline myopathy (20), a complex con-
genital skeletal muscle disease characterized by rod-like nema-
line bodies that are thought to cause muscle weakness (27, 28).
Similar to humans with mutations in LMOD3, mice in which
Lmod3 has been genetically knocked out exhibit skeletal muscle
weakness and the presence of nemaline bodies (29, 30). Notably,
similar rod-like structures representing elongated dense bodies
were frequently seen in visceral smooth muscle of Lmod1-null
mice. Although they did not have the cross-striations of 145-Å
periodicity seen in sarcomeric nemaline bodies, very similar
structures were described in gastric smooth muscle of a patient
diagnosed with nemaline myopathy (31). Of note, no such
structures have yet been reported in patients with MMIHS.
Fig. 7. Ultrastructure of bladder smooth muscle in postnatal Lmod1−/−
mice. Lmod1+/+ WT (A and C) versus Lmod1−/− mutant (B and D) SMC dense
bodies (arrowheads) that are much larger in mutants. Boxed regions in A
and B are shown at higher magnifications in C and D, respectively. [Scale
bars: A and B, 1 μm; C and D, 200 nm (black in Lower Left of each panel).]
Arrows point to glycogen granules, which are more prevalent in WT SMCs.
(E) Quantitative analysis of dense body length in WT (+/+) versus mutant
(−/−) SMCs (n = 35 for WT and n = 37 for mutant). Scatterplot depicts the
means ± SD (***P < 0.0001 by paired t test). (F) Quantitative analysis of
dense body concentration in WT (+/+) versus mutant (−/−) SMCs (n = 86 for
WT and n = 102 for mutant). Scatterplot depicts the mean ± SD (***P <
0.0001 by paired t test from two independent and blinded observers).
Fig. 6. LMOD1 knockdown in human intestinal SMCs decreases actin fila-
ment formation and contractility. (A) In vitro G-actin:F-actin assay in cultured
human intestinal smooth muscle cells (hiSMCs) with LMOD1 knockdown.
S and P refer to supernatant (G-actin) and pellet (F-actin), respectively.
(B) Collagen contractility assays (Left) in hiSMCs transfected with siCtrl or
siLMOD1 for 24 or 48 hours (H). Quantitative data are shown at Right with
Western blot of LMOD1 protein (Inset). Data shown are mean ± SD of three
independent experiments, performed in triplicate. ***P < 0.001 by unpaired
t test.
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Smooth muscle dense bodies are thought to act as anchor points
bridging the actin cytoskeleton with thin filaments (32, 33),
suggesting that changes in dense body characteristics reported
here uncouple the actin cytoskeleton from the contractile ap-
paratus of visceral smooth muscle-containing organs such as
stomach, intestine, and bladder of Lmod1−/− mice. Further
confirmation and characterization of visceral smooth muscle
nemaline-like bodies is needed in other animal models of
MMIHS, as well as MMIHS patients, to establish a pathological
role of these intriguing structures.
The cumulative mouse genetic data thus far would suggest an
essential role for each LMOD family member in the fidelity of
the actin cytoskeleton and normal contractile activity of smooth
(LMOD1), cardiac (LMOD2), and skeletal (LMOD3) muscle.
Because LMOD2 and LMOD3 are barely detectable in smooth
muscle-containing tissues (11, 12) and were not up-regulated in
tissues of Lmod1−/− mice (SI Appendix, Fig. S11B), no genetic
compensation was evident upon loss of LMOD1 in visceral
smooth muscle. Similarly, LMOD1 apparently cannot compensate
for loss in either LMOD2 or LMOD3. Future genetic comple-
mentation studies will be needed to provide insight into the
relative activities of each LMOD isoform in the complex setting
of the mouse.
Several unexpected findings emerged from the CRISPR-mediated
edits of Lmod1. First, the elimination of SRF-binding CArG
boxes upstream of Lmod1 had little to no effect on baseline
LMOD1 protein or mRNA expression. This finding should
be contrasted with an earlier report showing near abolishment
of CNN1, another SMC-restricted gene product (34), upon
CRISPR-mediated editing of a single intronic CArG box (17).
Similarly, a decrease in expression of smooth muscle myosin light
chain kinase with attenuated intestinal smooth muscle contrac-
tility was noted after deletion of an upstream CArG box (35).
The absence of change in LMOD1 expression with the double
CArG box mutation suggests that, whereas proximal promoter
CArG boxes are sufficient for Lmod1 promoter activity (12),
they are not necessary in their native genomic context, which
would imply that other, more distal CArG boxes coordinate
SRF-dependent expression of LMOD1 in both human and
mouse. Chromosome conformation capture assays may unveil
these and other important regulatory elements for Lmod1 ex-
pression. A second unexpected finding was the profound atten-
uation in transitional epithelium of the bladder and, to a lesser
extent, the stomach of Lmod1−/− mice, particularly in the post-
natal period when these organs exhibited dramatic distention. In
contrast, there was little evidence of epithelial loss in each seg-
ment of the intestine, perhaps due to the absence of mechanical
stress as seen in stomach and bladder. Another unanticipated
finding in Lmod1 mutant mice was the seemingly normal archi-
tecture and function of airways of the lung and vasculature, both
of which have a rich supply of smooth muscle. Similarly, patients
with MMIHS generally do not present with respiratory or car-
diovascular pathology. It must be stressed, however, that any
defects in these systems may be masked by the profound changes
in gastrointestinal and urinary tracts. Future work should further
assess the functional consequences of loss in LMOD1 in these
organ systems using more restrictive means of inactivating the
Lmod1 gene. Finally, it was somewhat surprising to have not
observed an obvious defect in actin filaments at the ultrastruc-
tural level, despite clear evidence of reduced filamentous actin as
measured by phalloidin staining of visceral organs of the mouse
deficient in LMOD1. We cannot explain this apparent paradox
although there could be subtle perturbations in filamentous actin
or its association with, for example, tropomyosin that are not
resolved by the electron microscope. It may prove informative to
generate an allelic series of mice in which the actin-binding,
tropomyosin, or Wiskott–Aldrich syndrome homology 2 do-
mains of LMOD1 (SI Appendix, Fig. S7) are mutated to pinpoint
the critical regions necessary for LMOD1 function in vivo.
It is interesting to contrast the findings reported here with
several other smooth muscle-restricted actin-binding proteins
that are dispensable for similar functional activity in these or-
gans, including CNN1 (17, 36), TAGLN (37), CSRP1 (38), and
CALD1 (39), which would suggest that compensatory pathways
exist to preserve normal organ function in the absence of each of
these actin-binding proteins. On the other hand, genetic in-
activation ofMyh11, encoding the major thick filament protein in
smooth muscle, leads to megacystis, a decrease in intestinal
motility, defective contraction of the bladder, and early postnatal
death, all of which are reminiscent of the Lmod1−/− phenotype
and human MMIHS (40). Further, smooth muscle-specific
knockout of myosin light chain kinase results in early postnatal
demise due to similar phenotypes observed in the Lmod1 and
Myh11 knockouts (41). Although human mutations in the latter
have not yet been documented, there is a report of a consan-
guineous family with a nonsense mutation in MYH11 associated
with MMIHS (10). Inactivation of SmoothelinA, encoding a vis-
ceral smooth muscle restricted actin-binding protein (42), results
in impaired intestinal contractility and 50% mortality in homo-
zygous mutants by postnatal day 20 (43); no human mutations
have yet been reported for SmoothelinA. Surprisingly, mice in
which the smooth muscle alpha actin gene (Acta2) is inactivated
survive with mild hypotension and reduced blood flow under
thermal challenge; no gastrointestinal or urinary pathologies
were reported (44). Compensatory increases in the skeletal alpha
actin isoform (ACTA1), as well as the dominant expression of
the gamma isoform of smooth muscle actin (ACTG2) in visceral
smooth muscle (45), likely compensate for loss of ACTA2 in the
gastrointestinal and urinary tracts. However, there are some de
novo mutations in human ACTA2 (R179H and R179C) that
associate with hypotonic bladder, malrotation, and intestinal
hypoperistalsis (46, 47). Notably, the Actg2 knockout mouse has
yet to be reported. In this context, levels of Actg2 mRNA and
other smooth muscle markers were unchanged in Lmod1−/−
mice, indicating that the MMIHS-like phenotype observed here
is not attributable to a secondary effect on expression of other
smooth muscle actin-binding proteins.
In summary, we have used human genetics coupled with CRISPR-
Cas9 genome editing in mice to establish LMOD1 as a disease gene
for MMIHS. Defining all genes linked to this devastating disorder
will provide insight into potential treatment strategies involving either
genome editing and/or viral-mediated therapies.
Fig. 8. Loss of LMOD1 results in reduced passive tensile strength and
agonist-induced contractility in intestinal rings. (A) Lmod1−/− jejunum ring
segments exhibit decreased tensile strength after dilation using wire
myography. Ring segments were mounted and equilibrated before being
dilated at set distances, and the passive tension of the ring segment was
recorded. (B) Representative myography traces showing force of contraction
versus time for control (Ctrl) and mutant (−/−) mouse jejunum ring segments
treated with 60 mM KCl or 1 μM carbachol. (C) Quantitation of data from B.
Shown are the means ± SD from n = 6 knockout or control groups receiving
KCl treatment and n = 4 for carbachol treatment (**P < 0.01 for all graphs by
paired t test analysis).
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Methods
SNP-Array Analysis. To determine chromosomal abnormalities in the patient
and to identify the presence of runs of homozygosity (ROH), we processed
250 ng of DNA on the Illumina HumanOmniExpress BeadChip v1 array
(Illumina, Inc.) using standard protocols. Normalized output was generated
using Genome Studio version 2011.1 (Illumina). ROH and copy number var-
iants (CNVs) were analyzed and visualized in Nexus CN8.0 (Biodiscovery Inc.).
ROH regions had to contain at least 50 probes and be larger than 1Mb in size
in line with established criteria (48, 49). CNVs were profiled according to
previously described prioritization methods (50). To determine the consan-
guinity coefficient (f) and the inbreeding coefficient (F), we used the ge-
nomic oligoarray and SNP-array evaluation tool v3.0 (51) and a 50 probes
minimum for ROH region.
Whole Exome Sequencing. Genomic DNA was fragmented using acoustic
technologies (Covaris, Inc.). Exome capture was performed with the Sure-
Select Human All Exon 50 Mb targeted exome enrichment kit v4 (Agilent
Technologies, Inc.), and the library was paired-end sequenced (2 × 101 bp)
using Illumina TruSeq v4 (Illumina). More than 5 Gb of raw sequence data
were processed using the NARWAHL pipeline and aligned to the
hg19 reference genome with Burrows–Wheeler Aligner v0.6.2 (52). The
Bayesian Genotyper, within the genome analyzer toolkit v1.2.9, was used to
determine variants, which were subsequently uploaded to Cartagenia Bench
NGS v4.1.8 (Cartagenia Inc.) for filtering and prioritization. CNVs and ROH
regions were exported from Biodiscovery Nexus CN8.0 to Cartagenia Bench
to inspect for overlap between identified ROH regions with rare variants.
We excluded variants with a high frequency in our in-house control cohort
(n = 200, with similar capture, alignment, and variant calls) and with an
allele frequency above 0.1% in public databases (ExAC release 0.3,
ESP6500SI-v2; 1000 Genomes Phase 3 release v5.20130502; and GoNL SNPs
and Indels release 5). Next, we annotated variants using the framework
described by Kircher et al. (53) and retained all splicing, coding, noncoding,
and nonsense variants with a CADD score of >20 representing the top 1%
ranked variants in the framework. The higher this Phred base-calling score is,
the more likely the variant has a deleterious effect (CADD v1.3; cadd.gs.
washington.edu/home). Heterozygous variants with an allele frequency
of ≤0.1% in the above public databases were considered of interest; for ho-
mozygous variants, a more lenient cutoff of 1% was used. The deleterious
variant is described in the ClinVar database (https://www.ncbi.nlm.nih.gov/
clinvar/) using the study description, “Whole exome sequencing studies in pa-
tients withmegacystis microcolon intestinal hypoperistalsis syndrome (MMIHS)”
under the following accession number: SCV000299346. Genes harboring can-
didate variants were inspected for their mRNA and protein expression patterns
in the Human Integrated Protein Expression Database and the Genotype Tissue
Expression Protein Database (54), incorporated in GeneCards (55), and over-
lapped with smooth muscle functioning in the Reactome Database (56).
Sanger Sequencing. PCR amplification across exon two of LMOD1 was per-
formed on genomic DNA isolated from peripheral blood lymphocytes to
confirm the nonsense mutation using sets of primers (SI Appendix, Table S4).
Sequencing reactions on purified PCR products were done on an ABI 3130XL
genetic analyzer (Applied Biosystems), and sequencing reads were analyzed
using SeqScape v2.5 software (Thermo Fisher Scientific).
CRISPR-Cas9 Genome Editing of Lmod1 in Mouse. All mice were housed in a
temperature- and humidity-controlled facility under the supervision of
trained laboratory support personnel. Guide RNAs (SI Appendix, Table S4)
targeted either to the paired CArG boxes or exon one of mouse Lmod1 were
cloned into the BbsI site of pX330-U6 chimeric BB-CBh-hSpCas9 plasmid
(42230; Addgene). The guide RNAs were in vitro transcribed using a HiScribe
T7 mRNA synthesis kit (New England BioLabs) and purified before assess-
ment on an Agilent Bioanalyzer as described (18). Mouse zygotes were
microinjected into the cytoplasm with Cas9 mRNA (100 ng/μL) and each
guide RNA (100 ng/μL each) as described previously (17, 57). After injection,
zygotes were cultured in KSOM+AA medium for 1 h before transfer into the
oviductal ampullae (10 to 15 zygotes per oviduct) of either CD1 (two-
component CRISPR) or C57BL/6J (three-component CRISPR) female mice
that had been mated, respectively, with vasectomized CD1 or C57BL/6J
males the previous evening. Genomic DNA was isolated from tail-snips or
toe-clips of founder mice by overnight proteinase K digestion. Primers
flanking exon one were used in a PCR to detect the deletion using AccuStart
II Supermix (Quanta). PCR conditions were as follows: 3 min incubation at
95 °C, followed by 35 cycles of 30 s at 95 °C, 30 s at 58 °C, and 30 s at 72 °C
and a 5-min extension at 72 °C. PCR genotyping of the CArG mutant mice
was done with a duplex PCR assay as previously described (17). All PCR
products were resolved in a 2% agarose gel.
A guide RNA design tool (58) was used to calculate the 10 most highly
ranked off-targets for each of the three guide RNAs. PCR primers flanking
each potential off-target sequence were designed and are listed in SI Ap-
pendix, Table S4. Adaptor sequences were added to the 5′ end of each
primer (5′-ACACTGACGACATGGTTCTACA-3′ for forward primers and
5′-TACGGTAGCAGAGACTTGGTCT-3′ for reverse primers). PCR was carried
out for 28 cycles (sequences 95 °C for 30 s, 53 °C for 30 s, and 72 °C for 30 s)
using AccuStart II Supermix (Quanta). All 30 PCR reactions were pooled and
Sanger sequenced by a core facility (Research Resources Center at the Uni-
versity of Illinois at Chicago). Sequence analysis of FASTQ files was done
using CRISPResso (19).
Quantitative Real-Time qPCR. RNA extraction from patient and control fi-
broblasts was done using an RNA extraction kit (Qiagen) according to the
manufacturer’s instructions. One microgram of total RNA was converted
into cDNA using an iScript cDNA synthesis kit (Bio-Rad). A mixture of cDNA
and primers (SI Appendix, Table S4) was used with a KAPA SYBR FAST qPCR
Kit (Kapa Biosystems), and real-time (RT)-qPCR was performed in an
IQ5 cycler machine (Bio-Rad). Expression levels were normalized with the
expression of two housekeeping genes (COPS5 and CLK2) and then averaged
and presented as fold changes. Total RNA was isolated from mouse tissues
using an miRNeasy Mini Kit (Qiagen), and cDNA was synthesized with an
iScript cDNA Synthesis Kit (Bio-Rad). RT-qPCR was performed using PerfeCTa
SYBR Green SuperMix (Quanta) and PCR primers (SI Appendix, Table S4) in a
CFX Connect Real-Time qPCR system (Bio-Rad).
Protein Isolation and Western Blotting. Fibroblasts (dermal) and human in-
testinal SMCs were washed with PBS and incubated with standard lysis buffer
and protease inhibitors (Roche) for 30 min on ice. Cell lysates were collected
by scraping and cleared by centrifugation at 9,500 × g for 15 min at 4 °C.
Protein was quantitated using bicinchoninic acid (Thermo Scientific), and
30 μg from each sample were loaded in a TGX precast 4% to 15% gel (Bio-
Rad). Proteins were transferred to nitrocellulose membranes and incubated
with primary antibodies to LMOD1 (1:200; Proteintech), alpha actin (1:250;
Cytoskeleton), and GAPDH (1:1,000; Millipore). Secondary antibodies used
were as follows: IRDye 800CW goat anti-mouse and IRDye 680RD goat anti-
rabbit (Li-Cor). Whole mouse tissue protein was extracted in Cell Lysis Buffer
(Cell Signaling) supplemented with complete mini EDTA-free protease inhibitor
mixture tablets (Roche) by mechanical homogenization. Cleared lysates were
resolved in 12% polyacrylamide gels, blotted to nitrocellulose, and incubated
with primary antibodies to LMOD1 (15117-1-AP, 1:800; Proteintech), TAGLN
(ab14106, 1:5,000; Abcam), MYH11 (BT-562, 1:500; Biomedical Technology), Pan-
actin (AAN01, 1:1,000; Cytoskeleton), and TUBB (2128, 1:1,000; Cell Signaling).
Immunohistochemistry/Immunofluorescence Microscopy. Formalin-fixed paraffin-
embedded human small intestinal tissues from controls were obtained from the
repository of the Department of Pathology, Erasmus University Medical Center.
Immunostaining was performed using specific antibody directed against LMOD1
(1:1,000; Proteintech), followed by a biotinylated secondary antibody and then
avidin–biotin complex with peroxidase. Sections were then incubated with 3′3′-
diaminobenzidine chromagen (Ventana) and then counterstained with hema-
toxylin. All images were taken with a Nanozoomer 2.0-HT (Hamamatsu Pho-
tonics) and analyzed using the Nanozoomer Digital Pathology viewer software
(Hamamatsu Photonics). Mouse tissues were fixed in methanol/H2O/acetic acid
(60:30:10, vol/vol) overnight, embedded in paraffin, and sectioned at 5 μm
thickness. After deparaffinization, slides were either stained with hematoxylin
and eosin (H&E) or underwent antigen retrieval using a pressure cooker set at
high pressure for 5 min in a pH 9 solution (Dako S2367) for primary antibody
staining. For TUNEL and Ki67 staining, slides were similarly treated with high
pressure steam in pH 6 solution (S1699; Dako) for 5 min and 10 min, respectively.
Primary antibodies were LMOD1 (1:100), Cy3-conjugated ACTA2 (C6198; Sigma),
MYH11 (BT-562, 1:100; Biomedical Technology), and Ki67 (652402, 1:100;
BioLegend); slides were incubated with each primary antibody overnight at 4 °C.
The next day, slides were washed in 1× PBS before incubation with secondary
antibody (AF-488 anti-rabbit, A11008, Thermo Scientific), AF-488 anti-mouse
(A11012; Thermo Scientific) for 1 h at room temperature. All images
were taken with a confocal microscope (FV 1000; Olympus) with voltage adjusted
to control (WT) slides and held constant for heterozygous and homozygous
null sections.
Transmission Electron Microscopy. Samples of jejunum intestine and bladder
were obtained from Lmod1−/− and WT mice after perfusion fixation with
2.5% glutaraldehyde/4% paraformaldehyde in Millonig’s phosphate buffer.
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Tissues were postfixed in buffered 1% osmium tetroxide, dehydrated, and
embedded into EPON/Araldite epoxy resin. Think sections (70 nm) on for-
mvar/carbon slot grids were imaged as described previously (59). Random
measurements of dense body length and concentration were made and
analyzed in a blinded manner by two independent investigators.
Cell Culture and Transfections. Primary human intestinal SMCs (hiSMCs) were
obtained from Sciencell Research Laboratories and cultured in SMC medium
mixed with 1% smooth muscle growth supplement and 1% penicillin/
streptomycin (Sciencell). Cells (300,000 per 35-mm dish) were maintained at
37 °C and 5% CO2 24 h before transfection. Cells were transfected with ei-
ther scrambled siRNA or siLMOD1 (100 nM per well; Ambion) using Lip-
ofectamine 2000 transfection reagent (Thermo Fisher Scientific). After 6 h,
the medium was refreshed with normal SMC medium, and cells were
allowed to grow for 72 h before analysis.
G-Actin/F-Actin Analysis. hiSMCs were transfected with scrambled siRNA or
siLMOD1 cells and after 72 h cells were harvested and lysed in detergent-
based lysis buffer that preserves monomeric actin (G-actin) and filamentous
actin (F-actin). Further isolation to separate both forms of actin from cell
debris was done according to the manufacturer’s instructions (BK037; Cy-
toskeleton). F-actin was pelleted by ultracentrifugation whereas G-actin
remained in the supernatant. Samples of supernatant and pellet were
mixed with 5× SDS sample buffer and loaded into an SDS/PAGE system for
Western blotting using an actin antibody (Cytoskeleton), GAPDH (Millipore),
and LMOD1 (Proteintech). Bladder tissue from WT and Lmod1 knockout
mice was frozen in liquid nitrogen before being assayed in the same manner
as hiSMCs.
Contractility Assays. Twenty-four hours after transfection with scrambled
siRNA or siLMOD1, hiSMCs were trypsinized and used for a collagen con-
tractility assay according to the manufacturer’s instructions (Cell Biolabs).
Jejunum from WT or Lmod1 knockout mice were rapidly dissected and
placed in ice-cold PSS buffer (130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4,
1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM dextrose, 0.026 mM EDTA, and
2.5 mM CaCl2). Rings of jejunum were mounted on a 610M Myograph (DMT)
in PSS buffer with constant oxygenation, and the temperature was main-
tained at 37 °C over a 30-min equilibration period. Passive tension was ap-
plied by mechanically expanding jejunum ring segments at 100- to 200-μm
intervals, and buffer was exchanged before tissues were allowed to equili-
brate for an additional 20 min. Tissues were treated with K-PSS buffer (PSS
with 60 mM KCl, 74.7 mM NaCl) or 100 μM carbachol to induce contraction.
For KCl treatment, the mean peak contractile force was taken for several
independent rounds of contraction over a 30-min period.
Statistics. Student’s unpaired t test was used to compare independent
datasets. For all data, error bars represent SD. Analysis of Mendelian ratios
was done using Chi Squared analysis to determine whether the difference
between expected and observed ratios was significant. A P value less than
0.05 was considered statistically significant. All statistical analyses were
performed using Prism 6.0 (GraphPad Software) or Microsoft Excel.
Study Approval. Ethical approval of an MMIHS patient from consanguineous
parents was granted by the Erasmus Medical Center Ethical Committee
(MedischEthischeToetsingsCommissie,Metc2011/148,ABR form,NL35920.042.11).
The family approvedawritten informed consent formbefore inclusion in the study.
Mouse experiments were approved by the Institutional Animal Care and Use
Committees of the University of Rochester School of Medicine and Dentistry
and the University of Nevada, Reno.
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Supplemental Figure Legends 
Supplemental Figure 1. Expression of LMOD1 in embryonic human intestine. 
LMOD1 is expressed (brown stain) in smooth muscle cells that constitute layers of the 
intestine (A-C) and bladder (D-F), including muscularis mucosa, blood vessels, and 
both muscle layers of the mucularis propria. (G) Western blot showing LMOD1 
expression in human aorta, bladder, and intestine, with undetectable expression in the 
kidney. 
Supplemental Figure 2. CRISPR-Cas9 targeting of CArG elements at Lmod1. (A) 
Schematic of Lmod1 proximal promoter (prom.) region containing two conserved CArG 
elements (vertical purple lines with indicated wild type sequences in black) showing 
position of gRNA (blue) immediately 5’ of a PAM sequence (red) located within the more 
proximal CArG box. Guide-RNA (Supplemental Table 4), Cas9 mRNA, and single-
stranded repair template (Supplemental Table 4) were injected into mouse fertilized 
eggs. The single-stranded oligonucleotide used in homology-directed repair contained 
the green substituted nucleotides within each CArG box; the PAM sequence was not 
mutated. (B) Alignment of Sanger sequencing confirmed CArG box (yellow) mutations 
in CArG-Mut mice. PAM sequence is highlighted in red. (C) RT-qPCR showing reduced 
Lmod1 expression in aorta of CArG-Mut mice, but no difference in other tissues. 
Average Lmod1 Ct value indicated above each bar. (D) Western blot showing no 
significant difference in LMOD1, MYH11, or TAGLN protein in CArG-WT or CArG-Mut 
bladder tissue. (E) Quantitation of LMOD1 protein in aorta and bladder of CArG-WT and 
CArG-Mut mice. No significant decrease in LMOD1 protein was observed in either 
tissue. Error bars here and in panel C are standard deviations around the mean. 
Supplemental Figure 3. Expression of SMC contractile proteins in Lmod1 mutant 
mice. (A) Western blot of LMOD1 protein (upper band, arrow) expression in aorta of 
indicated genotypes. The lower band here and elsewhere is non-specific as evidenced 
by its presence in the knockout aorta. (B) Western blot showing LMOD1 expression 
levels in bladder tissue from wild type (+/+), heterozygous (+/-), compound 
heterozygous (one allele carrying the 151 bp deletion of exon one and the other allele 
harboring mutations in both CArG elements at the Lmod1 promoter; MUT/-), or 
homozygous (-/-) deletion of Lmod1. 
Supplemental Figure 4. Non-specific binding of LMOD1 antibody. (A) 
Immunofluorescence microscopy showing LMOD1 and ACTA2 in sections of bladder 
tissue from wild type (WT) control or Lmod1-/- knockout (KO) mice, stained with either 
anti-LMOD1 antibody or normal IgG control. Note persistent weak signal with IgG 
control antibody and the thinning of the epithelial lining (ACTA2 negative stain) in 
bladder of KO. (B) Western blot of stomach and bladder tissue from control and 
Lmod1-/- mice depicting lower molecular weight bands that are not specific for LMOD1. 
Such nonspecific binding likely underscores the weak staining seen in Lmod1 knockout 
mouse tissues such as bladder in panel A above as well as in Figures 3, 4, and 5 of 
main text. 
Supplemental Figure 5. Increased proliferation in outer SMC layer of intestine in 
Lmod1 knockout. (A) Images of Ki-67 stained (green stain, white arrows) 
sections of intestine from Lmod1-/-  and control mice. White arrowheads indicate an 
increase in Ki-67 positive cells in the outer SMC layer of Lmod1-/- intestine. Sections 
were counterstained with MYH11 (red). Images taken with 40X objective. (B) 
Quantification of Ki-67+ cells in outer and inner SMC layers of the intestine. * 
= p value < 0.05. n = 9 for +/+, n= 14 for -/-. (C) Immunofluoresence microscopy images 
showing no detectable differences in TUNEL staining between Lmod1-/- and wild type 
control mice. Positive control sample of intestine was subjected to DNase 1 treatment. 
Supplemental Figure 6. Lmod1 knockout results in shortened intestinal length. 
(A) Gross pathology of stomach and whole intestine from Lmod1+/- and Lmod1-/- mice. 
Note the distended stomach and shortened intestinal length in Lmod1-/- tissues. (B) 
Quantification of intestinal length from part A. Lmod1 deletion results in significantly 
shorter intestinal length. (C) Quantification of colon diameter from H&E-stained sections 
from control and Lmod1-/- mice. Deletion of Lmod1 did not result in the presence of a 
microcolon. Error bars are standard deviations around the means. All statistics 
calculated using unpaired Student T test, ** = p value < 0.01. (D) H&E-stained sections 
from control (a, c) and Lmod1-/- (b, d) mice of aorta (a, b) and esophagus (c, d) showing 
no overt histopathological changes with Lmod1 deletion in these tissues. 
Supplemental Figure 7. Human versus mouse LMOD1. CLUSTALW alignment of 
human versus mouse LMOD1 protein. Amino acid numbers for each species are shown 
at right. The colored and labeled boxed regions represent approximate locations of 
known functional domains in LMOD1. The mouse mutation introduced by two-
component CRISPR editing is shown at top as a red boxed sequence labeled frameshift 
(fs) leading to a PTC (Stop sign; see also Figure 2C). The human point mutation is 
located further downstream and is indicated by a red box representing the SNP causing 
an Arginine (R) residue to become a PTC. 
Supplemental Figure 8. Lmod1 deletion results in decreased filamentous actin 
pelleted by ultracentrifugation. (A) In vivo G-actin:F-actin assay reveals that Lmod1 
deletion in primary mouse bladder tissue results in decreased levels of F-actin pelleted 
by ultracentrifugation (P). S and P refer to supernatant (G actin) and pellet (F-actin), 
respectively. (B) Quantification of in vivo G-actin:F-actin assay reveals that Lmod1 
deletion in primary mouse bladder tissue results in decreased levels of F-actin pelleted 
by ultracentrifugation. N = 7 for both knockout and control groups. Error bars represent 
the standard deviation around the mean. ** = p value < 0.01 using paired Student T 
test. 
Supplemental Figure 9. Lmod1 deletion results in decreased filamentous actin 
staining. Phalloidin staining (green) of duodenum and bladder from five control or five 
Lmod1-/- animals. Decreased phalloidin staining is consistently evident in Lmod1-/-
bladder tissue. 
Supplemental Figure 10. Transmission electron microscopy of dense bodies in 
Lmod1-/- bladder. Electron micrographs of dense bodies (black arrowheads) in smooth 
muscle of bladder (a-c, e-g) or intestine (d, h) tissue from Lmod1-/- (a-d) or Lmod1+/+ (e-
h) mice. Note abundance of glycogen granules (electron dense aggregates) in Lmod1+/+
versus Lmod1-/-. Scale bars are all 1 μm except for panel c which is 0.5 μm. 
Supplemental Figure 11. Passive tension analysis of mouse jejunum ring 
segments and lack of compensation by other leiomodin proteins. (A) Myography 
data showing real-time measurements of passive tension in mouse jejunum ring 
segments. Tissues were mounted in PSS buffer and equilibrated at 37˚C for 
approximately 20 minutes prior to being dilated at regular intervals (black dotted lines), 
and the resulting passive tension was recorded approximately 1 minute later (time 
indicated by light blue lines on X axis). (B) RT-qPCR data showing no up-regulation of 
Lmod2 or Lmod3 in tissues following Lmod1 deletion. 











Supplemental Table 1. Runs of homozygosity likely to be IBD 
Region Region Length Cytoband Location Genes Recessive variants Homozygous deleterious 
variants 
chr1:143,343,508-145,535,118 2191610 q21.1 55 0  
chr1:173,370,927-174,796,005 1425078 q25.1 30 0  
chr1:193,573,186-210,528,162 16954976 q31.2 - q32.2 212 12 NM_012134.2:c.1108C>T 
NM_001185156.1:c.541T>G 
chr1:248,058,844-249,250,621 1191777 q44 41 0  
chr1:39,434,967-40,549,847 1114880 p34.3 - p34.2 28 0  
chr10:95,863,499-97,045,599 1182100 q23.33 - q24.1 16 0  
chr12:33,710,632-35,800,000 2089368 p11.1 - q11 1 0  
chr13:20,806,399-22,561,134 1754735 q12.11 23 1  
chr13:96,306,895-97,414,036 1107141 q32.1 7 0  
chr15:76,540,526-77,848,747 1308221 q24.2 - q24.3 15 0  
chr16:46,450,037-48,939,622 2489585 q11.2 - q12.1 25 0  
chr2:119,938,409-120,962,478 1024069 q14.2 13 0  
chr2:87,375,359-90,240,473 2865114 p11.2 31 0  
chr2:95,395,757-115,363,347 19967590 q11.1 - q14.1 270 4 NM_153836.3:c.442-5G>A 
chr3:16,785,031-18,119,015 1333984 p24.3 6 0  
chr3:3,352,620-5,243,227 1890607 p26.2 - p26.1 11 0  
chr4:8,660,540-9,914,140 1253600 p16.1 34 0  
chr7:32,513,692-33,555,034 1041342 p14.3 19 0  
chr8:0-4,852,787 4852787 p23.3 - p23.2 32 1  
chr8:125,828,810-128,307,073 2478263 q24.13 - q24.21 39 1  
chr8:4,941,482-8,122,303 3180821 p23.2 - p23.1 60 0  
chr8:85,664,141-86,847,889 1183748 q21.2 15 0  
Included are Runs of homozygosity larger than 1 Mb, containing ≥ 50 consecutive probes. These regions are heterozygous in the 
parental samples and likely to be identical by descend. Most of the recessive variants (MAF ≤ 1%) are predicted to be benign, except 
the variants depicted in the last column. Recessive variants are depicted in table 2 
 
Supplemental Table 2. Homozygous recessive variants in putative IBD regions 
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1 200974176 G A A   KIF21B snp intronic   6 NM_001252100.1:c.733-115C>T   2.719 
1 201038809 G A A   CACNA1S snp intronic   18 NM_000069.2:c.2361-80C>T   3.588 
1 201453417 C T T   CSRP1 snp UTR3   6 NM_001193571.1:c.*424G>A   6.002 
1 201869033 G A A   LMOD1 snp exonic stopgain 2 NM_012134.2:c.1108C>T p.Arg370* 35 
1 202156089 A T T 0.001243781 PTPRVP snp ncRNA_intronic   18 NR_002930.2:c.3407-42A>T   3.909 
1 204192659 G A A 0.008624843 PLEKHA6 snp exonic nonsynonymous 22 NM_014935.4:c.3086C>T p.Ala1029Val 13.13 
1 204426534 T C C   PIK3C2B snp intronic   10 NM_002646.3:c.1713+322A>G   9.315 
1 207075619 A C C   IL24 snp intronic   6 NM_001185156.1:c.540+202A>C   0.266 
1 207076321 T G 
G 
0.003566428 IL24 snp exonic nonsynonymous 7 NM_001185156.1:c.541T>G p.Leu181Val 22.6 
1 207078220 T C C   FAIM3 snp UTR3   8 NM_005449.4:c.*144A>G   9.955 
1 207086885 G A A   FAIM3 snp intronic   2 NM_005449.4:c.373+219C>T   4.494 
1 207133613 A G 
G 
  FCAMR snp intronic   6 NM_001170631.1:c.1454+154T>C   3.249 
2 96940649 T C C   SNRNP200 snp UTR3   45 NM_014014.4:c.*101A>G   4.171 
2 102000169 C T T   CREG2 snp intronic   2 NM_153836.3:c.442-5G>A   8.603 
2 102636342 G A A   IL1R2 snp intronic   5 NM_004633.3:c.688+68G>A   5.461 
2 105897274 A T T   TGFBRAP1 snp intronic   6 NM_004257.5:c.1122-94T>A   3.669 
8 1719112 C T T   CLN8 snp UTR5   2 NM_018941.3:c.-109C>T   8.105 
8 126059429 T C C 0.0000165 KIAA0196 snp intronic   20 NM_014846.3:c.2504+20A>G   0.989 
13 21296049 G A A 0.001284481 IL17D snp exonic nonsynonymous 3 NM_138284.1:c.565G>A p.Ala189Thr 8.397 
All Homozygous recessive variants with an MAF below 1% in putative IBD regions.  
 
Supplemental Table 3. Off target sites of gRNAs and CRISPResso result 
gRNA Chromosome Coordinate Primer Primer Sequence Mismatch positions       Sequence 
Location Nearest Gene 
Percent 
indels from 
CRISPResso 
1 chr2:-168304560  
Forward TTTCTTCTTCCAACAGCGTTTC 
2:4:8:19 
CTACAGTGGCTAAGTACCCGTGG 
3’utr Nfatc2 0.4% 
Reverse GGTCCTGACCACAAAGTCATA 
1 chr2:+119860458 
Forward CAAACCTGCCCAGTCTACAT 
1:4:10:19 
TCAGAGTAGTTAAGTACCAGTGG 
intron Pla2g4b ND 
Reverse  CTTCCTTCTCCCAGACACTTC  
1 chr2:+155459613 
Forward TGGTGACAGGAAGAGTGGA  
5:6:8:20 
CCAACCTGGCTAAGTACCGCAAG 
exon Myh7b 0.3% 
Reverse CACTCCTTGTGCTAAGAGATGAA  
1 chr3:+81759039   
Forward CTTCTTGCCTTCTTCCCTCTG  
9:12:20 
CCAAAGTAACTCAGTACCGTTGG 
3’utr Ctso 0.0% 
Reverse CCGTTTCTTTACCCTCCATGAT  
1 chr11:-69611753  
Forward  GGTTCTCTAAGGGTGAGTGTAAG 
4:8:11:13 
CCACAGTGGCCATGTACCGGGAG 
exon Fgf11 0.6% 
Reverse GCTCAGGGCATGTGTGT 
1 chr7:+36220567   
Forward TGGTCCTTCTGTCTCCTTAGAT 
1:7:12:19 
GCAAAGCAGCTCAGTACCAGAAG 
exon Cep89 ND 
Reverse GCTCCCGCACTTACCTTT 
1 chr5:+44105813   
Forward TACTGGCTATGCACCAAAGG  
4:11:19:20 
CCACAGTAGCCAAGTACCTTCAG 
exon Cc2d2a 1.0% 
Reverse CCATCTTACAATCGTGGCTCT  
1 chr10:-94052876 
Forward CCAGGCAATTAGGTCTGGATT  
9:14:17:18 
CCAAAGTAACTAATTATTGGGAG
3’utr Tmc33 0.5% 
Reverse CTTGTGTTGTCTGTTGGTGTTC  
1 chr6:+32136129   
Forward GGGAAGCAAGCCAGTAAAGA  
1:10:19 
GCAAAGTAGTTAAGTACCTGCAG 
intron Plxna4 0.0% 
Reverse CTGCATCACCATCAGGAAAGA  
1 chr9:+40970879 
Forward ATAGAACGTGGTGTGGAAGTG  
1:06:13 
TCAAAATAGCTAGGTACCGGAGG 
intergenic Ubash3b ND 
Reverse ACTTCCACACTAAACTGGGTGT 
2 
chr15:+60655990 Forward GGGAGGGAAGGAAATAGAAACT 
3:06:07 
GGACTAGACTCACCTGCCGCAAG 
intron Fam84b 1.0% 
Reverse GCGAACTCGCCCTAGAAG  
2 
chr12:+85262753 Forward TACCTTCCCAGCTCCAACT  
1:3:5:6 
CGCCCGCACTCACCTGCCGCTGG 
intron Numb ND 
Reverse GGACAGGAAGAGTCAACCAATC  
2 chr6:+85290322   
Forward CCAAATAGAGGAGACCCTTACC  
4:5:6:8 
GGTGGACGCTCACCTGCCGCTGG 
intron Rab11fip5 0.2% 
Reverse GGCCCTTGACCTCTTCTTC  
2 chr8:-123093143  
Forward AGGAGGACAGATAGACAGACTT  
8:09:12 
GGTCTTCCTTCTCCTGCCGCAGG 
exon Gse1 0.5% 
Reverse GTGCCCAGCCTCATCTC  
2 chr1:-174475299  
Forward GCTCTTCCAGCTTCTGTTTCT  
4:5:10:20 
GGTTCTCACGCACCTGCCGTCGG 
exon Cfap45 0.0% 
Reverse TGTGGACCTTGAAGCATGAC  
2 chr11:+54864689 
Forward CTTTCTGACTCCCAAGGAAAGA  
5:9:10:12 
GGTCCTCAACCTCCTGCCGCAGG 
exon Ccdc69 ND 
Reverse ACTGTGCCAAGAGTGAGTG  
2 chr5:-121812464  
Forward CCTACCTCACCTTGTTCTTGTT  
2:7:10:19 
GCTCTTTACACACCTGCCACAGG 
exon Gm15800 0.7% 
Reverse AGCTAGGGTCAGCATCTCA  
2 chr19:-46384378  
Forward CAGGCATGTGCAATATTTGGG  
6:10:18 
GGTCTGCACCCACCTGCAGCAGG 
exon Nfkb2 0.9% 
Reverse GCAGATAGCCCACGTCATTTA  
2 chr15:-83161031  
Forward AGAGAGGGAGAGAGAGAGAGA  
1:3:8:18 
TGGCTTCTCTCACCTGCTGCAGG 
exon Arfgap3 ND 
Reverse CAGGAGACCACAGGACATTG  
2 chr2:-167433844  
Forward GGTGAGGAATTCAGGGCTTC  
3:5:6:19 
GGACCACACTCACCTGCCACCAG 
3’utr Ube2v1 0.3% 
Reverse GGCCTTTCTCTAGGCATCTTT 
3 chr6:-50334908   
Forward GCTTCACCTAAGGGACTTGTAG 
4:08:18 
TCCTGGTAGAATGAGCCTGATGG 
intron Osbp13 1.1% 
Reverse AGGTCTTACTGACTCCCACATA  
3 
chr2:+120960142 Forward GGCTGTCCTAGAACTCACTTTG  
4:5:8:17 
TCCTTGTGGAATGAGCTCGAGAG 
intergenic Lcmt2 0.6% 
Reverse GAGCGTCCTTAGGGAGATAGAT  
3 
chr18:+16761798 Forward AGAGATGGTCTGAGCAAAGATAAG  
3:5:11:12 
TCACAGTTGACAGAGCCCGAGGG 
intron Cdh2 ND 
Reverse CAGAGGGAGTAATGTTGGGATAAG 
3 chr19:+15937358 
Forward GAGGTCTGTGTGCAAAGGT  
3:5:7:19 
TCTCTGATGAATGAGCCCCACAG 
intergenic Psat1 0.4% 
Reverse GCTTCGGTTACTGCTGAGTT  
3 chr3:-60477413   
Forward CACACTGATGCCCAGGATAAA  
4:5:8:18 
TCCAAGTGGAATGAGCCAGAAAG 
intergenic Mbnl1 ND 
Reverse ACAGAGAAGTTACATGCAGAGAAG  
3 chr9:-57442270   
Forward TTGATCTGCTCCTTCAGGTATTC  
5:10:12:20 
TCCCTGTTGTAGGAGCCCGGCAG 
intron Ulk3 ND 
Reverse CTCAGGTCTGTGGGACATAAATAG  
3 chr2:-148578529  
Forward CATATAGTGGAGAGAAGCTCTTGG  
4:15:19 
TCCTGGTTGAATGATCCCCATAG 
intron Cst11 0.0% 
Reverse AGTGGTTGGCACAGTTCTAC  
3 chr2:-147438139  
Forward TCAACAGAGCACAGCAGAC  
4:7:8:18 
TCCTGGAAGAATGAGCCAGACAG 
intergenic Pax1 ND 
Reverse TTATGACAGCTTGAACCCTACC  
3 chr13:-52994868  
Forward CCGGTTTCTCAGTGTCCTTT  
3:8:10:14 
TCTCGGTGGCATGTGCCCGAGAG 
intron Auh 1.2% 
Reverse GGGTCATTTCGCTCTGAGTT  
3 chr16:-10681231  
Forward GGTGTGAAGACAGCGACTAT  
4:5:13:19 
TCCTTGTTGAATTAGCCCCAAGG 
intron Clec16a 0.0% 
Reverse GAGAGCAGTGGGTTGAGAAT  
Supplemental Table 4.  Oligonucleotides used for RT-PCR, genotyping, gRNA, and repair template 
Oligonucleotide Sequence 
Sequencing mutation in exon 2     
Human LMOD1 
Forward GGAGGTGGCCAAGAAAGAGG 
Reverse ATCATGAAGCCAGGGTCTCC 
qRT-PCR Human LMOD1 
Forward GAGGCCATGCTCAACTTCTG 
Reverse CTCTCCATTCTTGGCATCTG 
qRT-PCR Human COPS5 
Forward CCAGGAACCATTTGTAGCAG 
Reverse GTAGCCCTTTGGGTATGTCC 
qRT-PCR Human CLK2 
Forward TCGTTAGCACCTTAGGAGAGG 
Reverse TGATCTTCAGGGCAACTCG 
PCR genotyping primers for deletion 
in exon 1 Mouse Lmod1 
Forward GCCCAAAGAGCTGCAGTGC 
Reverse CTCACATCCACAGACATCTCTCTC 
qRT-PCR Exon 1 Mouse Lmod1 Forward TGTGGATGAAAGCAAGCAAGTG 
Reverse AATACCTCTGATGACCTTCTCCTC 
qRT-PCR Exon 2 Mouse Lmod1 
Forward CTGCCATCCGTTCTAGCAAC 
Reverse CAAGAGTCTGGGCAGTCATG 
qRT-PCR Mouse Gusb 
Forward CATCAGAAGCCGATTATCCAGAG 
Reverse TGTTTCCGATTACTCTCAGCG 
2-component CRISPR gRNA1 (exon1) CCAAAGTAGCTAAGTACCGG 
2-component CRISPR gRNA2 (exon 1) GGTCTTCACTCACCTGCCGC 
2-component CRISPR gRNA3 (exon 1) TCCCGGTTGAATGAGCCCGA 
3-component CRISPR (CArG boxes) AAACTGCTCTGTACTAAATT 
ssoligo for 3-component CRISPR editing of 
CArG boxes 
TCCTGCGGCTTCTGCCAGCCTTTGCATTTTTCTCTTTTTCTCAT 
TGCGTGGCCCCCTTGTGGGTAAAAGGCTAAACTGCTCTGTAGG 
GAATTTGGTCACGCAGCGCTCCAAGATTCCCTGGAATGTCCTC 
